Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Evelyn Despierre(KU Leuven), Antonio Jimeno(University of Colorado Cancer Center)
Targeted Oncology
May 25, 2015
10.1007/s11523-015-0369-6
Cited by 29

Related Papers

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2017|378
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
|European Journal of Cancer|2018|267
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck
|JAMA Oncology|2018|111